Leiden, the Netherlands, March 13, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the ...

The global stem cell therapy market is poised for remarkable growth, with revenues projected to escalate from USD 394.50 million in 2024 to USD 2,612.92 million by 2033, reflecting a compelling ...

Support the shows you love. One-of-a-kind podcasts from WDET bring you engaging conversations about everything from music to mental health.

Recent Business Highlights Zerlasiran for Cardiovascular Disease Received positive regulatory feedback from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and the ...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024. "Pepaxti sales increased about 35 percent ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 ...